| P50 | author | Allen C. Cheng | Q40758533 |
| P2093 | author name string | Susan Poole | |
| | Michael J Dooley | |
| | Carmela E Corallo | |
| | Cecile Aubron | |
| | Maya O Nunn | |
| P2860 | cites work | Vancomycin: a 50-year reassessment | Q34472258 |
| | Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia | Q34783668 |
| | Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients | Q34991274 |
| | Application of a Bayesian method to monitor and adjust vancomycin dosage regimens | Q35261758 |
| | Comparison of steady-state pharmacokinetics of two dosage regimens of vancomycin in normal volunteers | Q35537659 |
| | Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity | Q36538707 |
| | Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists | Q37537565 |
| | Vancomycin-induced neutropenia complicating bone marrow recovery in a patient with leukemia. Case report and review of the literature | Q39719615 |
| | Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices | Q39771366 |
| | Population pharmacokinetic parameters of vancomycin in critically ill patients | Q40290397 |
| | Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus | Q40542104 |
| | ORIGINAL ARTICLE: Investigation of the prediction accuracy of vancomycin concentrations determined by patient-specific parameters as estimated by Bayesian analysis | Q42910842 |
| | Vancomycin dosage optimization in patients with malignant haematological disease by pharmacokinetic/pharmacodynamic analysis. | Q44932809 |
| | Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections | Q45127594 |
| | High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity | Q45302930 |
| | Population pharmacokinetic analysis of vancomycin in patients with gram-positive infections and the influence of infectious disease type. | Q45937025 |
| | A review of vancomycin therapeutic drug monitoring recommendations in Scotland | Q46694964 |
| | Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia | Q46826194 |
| | Some suggestions for measuring predictive performance | Q52875851 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | software | Q7397 |
| | pharmacokinetics | Q323936 |
| | vancomycin | Q424027 |
| | modelling software | Q112123596 |
| P304 | page(s) | 757-763 | |
| P577 | publication date | 2011-06-07 | |
| P1433 | published in | Annals of Pharmacotherapy | Q4767858 |
| P1476 | title | Vancomycin dosing: assessment of time to therapeutic concentration and predictive accuracy of pharmacokinetic modeling software | |
| P478 | volume | 45 | |